Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00248833 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.
A Phase 1 study, sponsored by U.S. Army Medical Research and Development Command.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT00248833 is a Phase 1 study that has completed, run by U.S. Army Medical Research and Development Command. The registered enrollment target is 34 participants.
The verdict
NCT00248833, a Phase 1 study, has completed, sponsored by U.S. Army Medical Research and Development Command.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis. This study will vaccinate three groups of people. In the first 2 groups, the study will be double-blinded. This means that neither the volunteer or the medical team will know which formulation of the vaccine was administered. The third group of volunteers and the medical team will know that they are receiving the higher dose of the vaccine.
Interventions
- BIOLOGICAL 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
- BIOLOGICAL 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2005-12-05 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00248833
The ClinicalTrials.gov registry entry for NCT00248833 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is U.S. Army Medical Research and Development Command, which has 77 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is the first listed.
NCT00248833 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00248833 about?
NCT00248833 is a clinical study titled "Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.". The purpose of this study is to determine if the vaccine called Group B Meningococcal 44/76 MOS NOMV 5D Vaccine is safe and free from side effects and if it will protect people from meningitis. This study will vaccinate three groups of people. In the first 2 groups, the study will be double-blinded...
What is the current status of trial NCT00248833?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2005-12-05. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00248833?
The interventions under investigation include: 25ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine (BIOLOGICAL), 50ug Group B Meningococcal 44/76 MOS NOMV 5D Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00248833?
This trial is sponsored by U.S. Army Medical Research and Development Command, which has 77 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.